Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: A NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 238-244

  Kollmannsberger, C ^a   Hirte, H ^b   Siu, L L ^c   Mazurka, J ^b   Chi, K ^a   Elit, L ^b   Walsh, W ^d   Sederias, J ^d   Doyle, A ^e   Eisenhauer, E A ^d   Oza, A M ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carboplatin; Combination; Paclitaxel; Phase I; Temsirolimus

Indexed keywords

CARBOPLATIN; PACLITAXEL; TEMSIROLIMUS;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BILE DUCT CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HEARTBURN; HOT FLUSH; HUMAN; INFECTION; INJECTION SITE REACTION; INSOMNIA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINITIS; RIGOR; SKIN BRUISING; SOLID TUMOR; TASTE DISORDER; THROMBOCYTOPENIA; URETHRA CANCER; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; VAGINA CANCER; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SIROLIMUS;

EID: 80052030314     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr063     Document Type: Article

References (27)

1. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001; 98: 136-141.
2. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
3. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/ mTOR. Genes Dev 2001; 15: 807-826.
4. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): proand anti-apoptotic. Cell Death Differ 2002; 9: 99-100.
5. Oza AM, Elit L, Provencher D et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008; 26 (Suppl): (Abstr 5516).
6. Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005; 104: 1045-1048.
7. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294-5304.
8. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23: 5314-5322.
9. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
10. Ito D, Fujimoto K, Mori T et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 2006; 118: 2337-2343.
11. Geoerger B, Kerr K, Tang CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527-1532.
12. Wu C, Wangpaichitr M, Feun L et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005; 4: 25.
13. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-2831.
14. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19: 4048-4053.
15. Humber C, Tierney J, Symonds P et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2005; CD003915.
16. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
17. Kelly K, Crowley J, Bunn PA Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
18. Briasoulis E, Kalofonos H, Bafaloukos D et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18: 3101-3107.
19. Bookman MA, McGuire WP 3rd, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-1902.
20. Punt CJ, Boni J, Bruntsch U et al. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14: 931-937.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
22. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-2347.
23. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
24. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
25. Sarkaria JN, Galanis E, Wu W et al. NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J Clin Oncol 2009; 27 (Suppl): 15s. (Abstr 2019).
26. Guo H, Zhou T, Jiang D et al. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol 2007; 81: 10072-10080.
27. Matsumoto A, Ichikawa T, Nakao K et al. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol 2009; 44: 856-863.